Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Reviews in Endocrine and Metabolic Disorders
Erschienen in:

08.08.2023

Drug-induced hyperinsulinemic hypoglycemia: An update on pathophysiology and treatment

verfasst von: Evelina Maines, Silvana Anna Maria Urru, Letizia Leonardi, Elisabetta Fancellu, Annalisa Campomori, Giovanni Piccoli, Arianna Maiorana, Massimo Soffiati, Roberto Franceschi

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

The initial step for the differential diagnosis of hypoglycemia is to determine whether it is hyperinsulinemic or non hyperinsulinemic. Existing literature discusses drug-related hypoglycemia, but it misses a focus on drug-induced hyperinsulinemic hypoglycemia (DHH). Here we reviewed the association existing between drugs and hyperinsulinemic hypoglycemia. We primarily selected on the main electronic databases (MEDLINE, EMBASE, Web of Science, and SCOPUS) the reviews on drug-induced hypoglycemia. Among the drugs listed in the reviews, we selected the ones linked to an increase in insulin secretion. For the drugs missing a clear association with insulin secretion, we investigated the putative mechanism underlying hypoglycemia referring to the original papers. Our review provides a list of the most common agents associated with hyperinsulinemic hypoglycemia (HH), in order to facilitate both the recognition and the prevention of DHH. We also collected data about the responsiveness of DHH to diazoxide or octreotide.
Literatur
1.
Ben Salem C, Fathallah N, Hmouda H, Bouraoui K. Drug-induced hypoglycaemia: an update. Drug Saf. 2011;34(1):21–45.PubMedCrossRef
2.
Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management Drug Saf. 1996;15(2):135–57.PubMedCrossRef
3.
4.
Chan TY, Lee KK, Chan AW, Critchley JA. Utilization of antidiabetic drugs in Hong Kong: relation to the common occurrence of antidiabetic drug-induced hypoglycemia amongst acute medical admissions and the relative prevalence of NIDDM. Int J Clin Pharmacol Ther. 1996;34(1):43–6.PubMed
5.
Kilbridge PM, Campbell UC, Cozart HB, Mojarrad MG. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc. 2006;13(4):372–7.
6.
Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993;118(7):529–39.PubMedCrossRef
7.
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652–8.PubMedCrossRef
8.
Ferreira JP, Araújo F, Dores J, Santos L, Pape E, Reis M, Chipepo Á, Nascimento E, Baptista A, Pires V, Marques C, Lages AS, Conceição J, Laires PA, Pelicano-Romano J, Alão S. Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach. Diabetes Ther. 2020;11(10):2237–55.PubMedPubMedCentralCrossRef
9.
Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS ONE. 2016;11(9): e0162951.PubMedPubMedCentralCrossRef
10.
Helms, K. Kelley, K. Drug-induced Hypoglycemia. In: Rigobelo, EC. Hypoglycemia – Causes and Occurrences. InTech. 2011:113-30.
11.
Barbosa ADM, Junior IF, Lima GM. Neonatal Hypoglycemia. IntechOpen. 2018;63–81.
12.
Synnes A. Screening for Neonatal Hypoglycemia After Fetal Exposure to β-Blockers. Pediatrics. 2016;138(3): e20161691.PubMedCrossRef
13.
Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Maeda A, Fischer MA, Hernandez-Diaz S, Huybrechts KF. Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics. 2016;138(3): e20160731.PubMedPubMedCentralCrossRef
14.
Çoban D, Kurtoğlu S, Akın MA, Akçakuş M, Güneş T. Neonatal episodic hypoglycemia: a finding of valproic acid withdrawal. J Clin Res Pediatr Endocrinol. 2010;2(2):92–4.PubMedPubMedCentralCrossRef
15.
Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016;138(5): e20160181.PubMedCrossRef
16.
Svenningsen NW, Holmquist P, Ingemarsson I. Antenatal management of terbutaline–effects on infants born preterm. J Singapore Paediatr Soc. 1985;27(3–4):208–14.PubMed
17.
Shimokawa S, Sakata A, Suga Y, Isoda K, Itai S, Nagase K, Shimada T, Sai Y. Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study. J Pharm Health Care Sci. 2019;16(5):7.CrossRef
18.
Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009;94(3):741–5.PubMedCrossRef
19.
Vue MH, Setter SM. Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia. Diabetes Spectrum. 2011;24(3):171–7.CrossRef
20.
Maiorana A, Dionisi-Vici C. Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties. J Inherit Metab Dis. 2017;40(4):531–42.PubMedCrossRef
21.
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709–28.
22.
Ng CL. Hypoglycaemia in nondiabetic patients - an evidence. Aust Fam Physician. 2010;39(6):399–404.PubMed
23.
Seltzer HS. Drug-induced hypoglycemia. A review based on 473 cases. Diabetes. 1972;21(9):955–66.
24.
Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012;6(11):122.CrossRef
25.
Little GL, Boniface KS. Are one or two dangerous? Sulfonylurea exposure in toddlers. J Emerg Med. 2005;28(3):305–10.PubMedCrossRef
26.
27.
Fleseriu M, Skugor M, Chinnappa P, Siraj ES. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract. 2006;12(6):635–40.
28.
Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, Sosale A, Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci. 2013;9(5):936–43.PubMedPubMedCentralCrossRef
29.
Fasano CJ, Rowden AK. Successful treatment of repaglinide-induced hypoglycemia with octreotide. Am J Emerg Med. 2009;27(6):756.e3-4.PubMedCrossRef
30.
Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S223–31.
31.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–35.
32.
Plöckinger U, Holst JJ, Messerschmidt D, Hopfenmüller W, Quabbe HJ. Octreotide suppresses the incretin glucagon-like peptide (7–36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. Eur J Endocrinol. 1999;140(6):538–44.PubMedCrossRef
33.
Solverson KJ, Lee H, Doig CJ. Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia. CJEM. 2018;20(S2):S61–3.PubMedCrossRef
34.
Yamaguchi S, Ikejima M, Furukawa A, Abe M, Nakazaki M, Ishihara H. Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor. Diabetes Res Clin Pract. 2015;109(2):e8–10.PubMedCrossRef
35.
Roustit M, Blondel E, Villier C, Fonrose X, Mallaret MP. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother. 2010;44(4):764–7.PubMedCrossRef
36.
Frankel MC, Leslie BR, Sax FL, Soave R. Trimethoprim–sulfamethoxazole-related hypoglycemia in a patient with renal failure. N Y State J Med. 1984;84(1):30–1.PubMed
37.
Arem R, Garber AJ, Field JB. Sulfonamide-induced hypoglycemia in chronic renal failure. Arch Intern Med. 1983;143(4):827–9.PubMedCrossRef
38.
Poretsky L, Moses AC. Hypoglycemia associated with trimethoprim/sulfamethoxazole therapy. Diabetes Care. 1984 Sep-Oct;7(5):508–9.
39.
Rossio R, Arcudi S, Peyvandi F, Piconi S. Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review. Int J Clin Pharmacol Ther. 2018;56(2):86–9.PubMedCrossRef
40.
Tan A, Holmes HM, Kuo YF, Raji MA, Goodwin JS. Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use. J Gerontol A Biol Sci Med Sci. 2015;70(2):247–54.PubMedCrossRef
41.
Gonc EN, Turul T, Yordam N, Ersoy F. Trimethoprim-sulfamethoxazole induced prolonged hypoglycemia in an infant with MHC class II deficiency: diazoxide as a treatment option. J Pediatr Endocrinol Metab. 2003;16(9):1307–9.PubMed
42.
Bellucci PN, González Bagnes MF, Di Girolamo G, González CD. Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus. J Pharm Pract. 2017;30(5):549–56.PubMedCrossRef
43.
Li J, Zhang N, Ye B, Ju W, Orser B, Fox JE, Wheeler MB, Wang Q, Lu WY. Non-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channels. Br J Pharmacol. 2007;151(4):483–93.PubMedPubMedCentralCrossRef
44.
Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol. 2004;497(1):111–7.PubMedCrossRef
45.
LeBlanc M, Bélanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy. 2004;24(7):926–31.PubMedCrossRef
46.
47.
Davis TM, Dembo LG, Kaye-Eddie SA, Hewitt BJ, Hislop RG, Batty KT. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol. 1996;42(4):415–21.PubMedPubMedCentralCrossRef
48.
White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S, Williamson DH, Turner RC. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med. 1983;309(2):61–6.PubMedCrossRef
49.
Phillips RE, Warrell DA, Looareesuwan S, Turner RC, Bloom SR, Quantrill D, Moore AR. Effectiveness of SMS 201–995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet. 1986;1(8483):713–6.PubMedCrossRef
50.
Phillips RE, Looareesuwan S, Molyneux ME, Hatz C, Warrell DA. Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria: treatment with Sandostatin. Q J Med. 1993;86(4):233–40.PubMed
51.
Negishi M, Shimomura K, Proks P, Mori M, Shimomura Y. Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009;26(1):76–8.PubMedCrossRef
52.
Horie M, Ishida-Takahashi A, Ai T, Nishimoto T, Tsuura Y, Ishida H, Seino Y, Sasayama S. Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs. Cardiovasc Res. 1997;34(1):69–72.PubMedCrossRef
53.
Phillips RE, Looareesuwan S, White NJ, Chanthavanich P, Karbwang J, Supanaranond W, Turner RC, Warrell DA. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed). 1986;292(6531):1319–21.PubMedCrossRef
54.
Goldberg IJ, Brown LK, Rayfield EJ. Disopyramide (Norpace)-induced hypoglycemia. Am J Med. 1980;69(3):463–6.PubMedCrossRef
55.
Hilleman DE, Mohiuddin SM, Ahmed IS, Dahl JM. Cibenzoline-induced hypoglycemia. Drug Intell Clin Pharm. 1987;21(1 Pt 1):38–40.PubMed
56.
Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C. Disopyramide-induced hypoglycemia: case report and review of the literature. Fundam Clin Pharmacol. 1989;3(5):527–35.PubMedCrossRef
57.
Ratna Tuladhar L, Lal Shrestha S, Bimali S, Bhusal S, Khadka P. Drug-drug Interactions between Hypoglycemic and Non-hypoglycemic Medication in Diabetic Patients with Comorbidities in a Tertiary Care Center: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2021;59(243):1125–30.PubMedCrossRef
58.
Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Free R, Lee J, Zong W, Xue X, Shrestha S, Brissova M, Logan RW, Wollheim CB, Trucco M, Yechoor VK, Sibley DR, Bottino R, Freyberg Z. Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Transl Psychiatry. 2021;11(1):59.PubMedPubMedCentralCrossRef
59.
Rickels MR, Perez EM, Peleckis AJ, Alshehabi E, Nguyen HL, Stefanovski D, Rickels K, Teff KL. Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia. Am J Physiol Endocrinol Metab. 2018;315(2):E250–7.PubMedCrossRef
60.
Omi T, Riku K, Fukumoto M, Kanai K, Omura Y, Takada H, Matunaga H. Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion. Case Rep Psychiatry. 2016;2016:1805414.PubMedPubMedCentral
61.
Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand. 2009;119(6):457–65.PubMedPubMedCentralCrossRef
62.
van Keulen K, van der Linden PD, Souverein PC, Heerdink ER, Egberts AC, Knol W. Risk of Hospitalization for Hypoglycemia in Older Patients with Diabetes Using Antipsychotic Drugs. Am J Geriatr Psychiatry. 2015;23(11):1144–53.PubMedCrossRef
63.
Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front Neurosci. 2017;28(11):432.CrossRef
64.
Ochi S, Abe M, Shimizu H, Iga J, Ueno S. Hypoglycemia with atypical antipsychotics, but not with typical antipsychotics: A case report. Clin Neuropsychopharm Ther. 2020;11:5–8.
65.
Broadstone VL, Pfeifer MA, Bajaj V, Stagner JI, Samols E. Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes. 1987;36(8):932–7.PubMedCrossRef
66.
Filipponi P, Gregorio F, Ferrandina C, Nicoletti I, Mannarelli C, Pippi R, Santeusanio F. Alpha-adrenergic system in the modulation of pancreatic A and B cell function in normal rats. Diabetes Res Clin Pract. 1986;2(6):325–36.
67.
Scholl JH, van Eekeren R, van Puijenbroek EP. Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients. Br J Clin Pharmacol. 2015;79(5):870–1.PubMedPubMedCentralCrossRef
68.
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271(10):5768–76.PubMedCrossRef
69.
Epstein MF, Nicholls E, Stubblefield PG. Neonatal hypoglycemia after beta-sympathomimetic tocolytic therapy. J Pediatr. 1979;94(3):449–53.PubMedCrossRef
70.
Procianoy RS, Pinheiro CE. Neonatal hyperinsulinism after short-term maternal beta sympathomimetic therapy. J Pediatr. 1982;101(4):612–4.PubMedCrossRef
71.
Kurtoglu S, Akcakus M, Keskin M, Ozcan A, Hussain K. Severe hyperinsulinaemic hypoglycaemia in a baby born to a mother taking oral ritodrine therapy for preterm labour. Horm Res. 2005;64(2):61–3.PubMed
72.
Caldwell G, Scougall I, Boddy K, Toft AD. Fasting hyperinsulinemic hypoglycemia after ritodrine therapy for premature labor. Obstet Gynecol. 1987;70(3 Pt 2):478–80.PubMed
73.
Ozdemir D, Yilmaz E, Duman M, Unal N, Tuncok Y. Hypoglycemia after albuterol overdose in a pediatric patient. Pediatr Emerg Care. 2004;20(7):464–5.PubMedCrossRef
74.
Saï P, Boillot D, Boitard C, Debray-Sachs M, Reach G, Assan R. Pentamidine, a new diabetogenic drug in laboratory rodents. Diabetologia. 1983;25(5):418–23.PubMedCrossRef
75.
Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther. 1986;39(3):271–5.PubMedCrossRef
76.
Assan R, Perronne C, Assan D, Chotard L, Mayaud C, Matheron S, Zucman D. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care. 1995;18(1):47–55.
77.
Fitzgerald DB, Young IS. Reversal of pentamidine-induced hypoglycaemia with oral diazoxide. J Trop Med Hyg. 1984;87(1):15–9.PubMed
78.
Radenković M, Stojanović M, Prostran M. Experimental diabetes induced by alloxan and streptozotocin: The current state of the art. J Pharmacol Toxicol Methods. 2016;78:13–31.
79.
Censi S, Albergoni MP, Gallo N, Plebani M, Boscaro M, Betterle C. Insulin autoimmune syndrome (Hirata’s disease) in an Italian patient: a case report and review of the literature. Clin Chem Lab Med. 2018;56(6):889–95.PubMedCrossRef
80.
Uchigata Y, Hirata Y, Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83(1):e19-20.PubMedCrossRef
81.
82.
Yamada T, Imai J, Ishigaki Y, Hinokio Y, Oka Y, Katagiri H. Possible relevance of HLA-DRB1*0403 haplotype in insulin autoimmune syndrome induced by alpha-lipoic acid, used as a dietary supplement. Diabetes Care. 2007;30(12): e131.PubMedCrossRef
83.
Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med. 1994;180(3):873–83.PubMedCrossRef
84.
Batra CM, Kumar K, Goyal M Sr. Steroid-Refractory Insulin Autoimmune Syndrome Treated With Rituximab and Continuous Glucose Monitoring. Cureus. 2021;13(7): e16513.PubMedPubMedCentral
85.
Schlemper RJ, Uchigata Y, Frölich M, Vingerhoeds AC, Meinders AE. Recurrent hypoglycaemia caused by the insulin autoimmune syndrome: the first Dutch case. Neth J Med. 1996;48(5):188–92.PubMedCrossRef
86.
Giugliano D, Ceriello A, Saccomanno F, Quatraro A, Paolisso G, D’Onofrio F. Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1985;61(1):160–6.PubMedCrossRef
87.
Wasner HK, Weber S, Partke HJ, Amini-Hadi-Kiashar H. Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action. Acta Diabetol. 1994;31(4):175–82.PubMedCrossRef
88.
Hosono S, Ohno T, Ojima K, Kimoto H, Nagoshi R, Shimizu M, Nozawa M. Intractable hypoglycemia following indomethacin therapy for patent ductus arteriosus. Pediatr Int. 2000;42(4):372–4.PubMedCrossRef
89.
Sadeq OR, Jarbawu MMA. The effect of indomethacin on glucose serum. International Journal of Research in Applied, Natural and Social Sciences (IMPACT: IJRANSS). 2017;5(4):1–8.
90.
Makunts TUA, Atayee R, Abagyan R. Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids. Sci Rep. 2019;9(1):12490.PubMedPubMedCentralCrossRef
91.
Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, Lelong-Boulouard V, Le Boisselier R, Fedrizzi S, Alexandre J, Humbert X. Comparative study of hypoglycaemia induced by opioids. Is it a class effect? Expert Opin Drug Saf. 2019;18(10):987–992.
92.
Green IC, Perrin D, Pedley KC, Leslie RD, Pyke DA. Effect of enkephalins and morphine on insulin secretion from isolated rat islets. Diabetologia. 1980;19(2):158–61.PubMedCrossRef
93.
Yamada J, Sugimoto Y, Kimura I, Takeuchi N, Horisaka K. Serotonin-induced hypoglycemia and increased serum insulin levels in mice. Life Sci. 1989;45(20):1931–6.PubMedCrossRef
94.
Green IC, Ray K, Perrin D. Opioid peptide effects on insulin release and c-AMP in islets of Langerhans. Horm Metab Res. 1983;15(3):124–8.PubMedCrossRef
95.
Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–70.PubMed
96.
Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223(1):5–8.PubMedCrossRef
97.
Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van Havenbergh T, Smet M, Van Acker K. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85(6):2215–22.PubMedCrossRef
98.
99.
Masharani U, Alba D. Methadone-Associated Hypoglycemia in Chronic Renal Failure Masquerading as an Insulinoma. Pain Med. 2018;19(9):1876–8.PubMedCrossRef
100.
101.
Moryl N, Pope J, Obbens E. Hypoglycemia during rapid methadone dose escalation. J Opioid Manag. 2013;9(1):29–34.
102.
103.
Makunts TUA, Atayee RS, Abagyan R. Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids. Sci Rep. 2019;9(1):12490.
104.
Rigas JR, Francis PA, Miller VA, Tong WP, Roistacher N, Kris MG, Orazem JP, Young CW, Warrell RP Jr. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol. 1995;35(6):483–8.PubMedCrossRef
Metadaten
Titel
Drug-induced hyperinsulinemic hypoglycemia: An update on pathophysiology and treatment
verfasst von
Evelina Maines
Silvana Anna Maria Urru
Letizia Leonardi
Elisabetta Fancellu
Annalisa Campomori
Giovanni Piccoli
Arianna Maiorana
Massimo Soffiati
Roberto Franceschi
Publikationsdatum
08.08.2023
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 6/2023
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-023-09828-y

Weitere Artikel der Ausgabe 6/2023

Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies

Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis

Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer: a systematic review and meta-analysis

Beyond glycemia: Comparing tirzepatide to GLP-1 analogues

  • Open Access

White adipose tissue mitochondrial bioenergetics in metabolic diseases

Vitamin D status and supplementation before and after Bariatric Surgery: Recommendations based on a systematic review and meta-analysis

  • Open Access

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise